18.42

1.13% -0.21

Enliven Therapeutics Inc (ELVN)

Overview News Price History Option Chain Financials Discussions Forecast

Enliven Therapeutics Inc stock is traded at $18.42, with a volume of 511.96K. It is down -1.13% in the last 24 hours and up +11.50% over the past month. Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Previous Close:

$18.63

Open:

$18.71

24h Volume:

511.96K

Relative Volume:

1.91

Market Cap:

$1.01B

Revenue:

Net Income/Loss:

$-85.21M

P/E Ratio:

-9.746

EPS:

-1.89

Net Cash Flow:

$-68.53M

1W Performance:

-10.19%

1M Performance:

+11.50%

6M Performance:

-36.40%

1Y Performance:

-22.93%

1-Day Range:

$18.25

$19.67

1-Week Range:

$17.76

$20.60

52-Week Range:

$13.30

$30.03

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name

Enliven Therapeutics Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

720-647-8519

Address

6200 LOOKOUT ROAD, BOULDER

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ELVN's Discussions on Twitter

Compare ELVN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ELVN Enliven Therapeutics Inc	18.42	1.01B	0	-85.21M	-68.53M	-1.89
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-13-24	Initiated	BTIG Research	Buy
Sep-09-24	Initiated	H.C. Wainwright	Buy
Jun-11-24	Initiated	Robert W. Baird	Outperform
Apr-09-24	Initiated	Mizuho	Buy
Mar-29-23	Initiated	Jefferies	Buy

Enliven Therapeutics Inc Stock (ELVN) Latest News

May 05, 2025

Wells Fargo & Company MN Has $375,000 Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

May 05, 2025

Invesco Ltd. Buys 508 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

May 05, 2025

May 04, 2025

Barclays PLC Has $1.45 Million Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

May 04, 2025

May 02, 2025

Enliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week Low on Insider Selling - Defense World

May 02, 2025

JPMorgan Chase & Co. Trims Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

May 02, 2025

May 01, 2025

Enliven (ELVN) Gains Attention as EHA Data Release Approaches | - GuruFocus

May 01, 2025

Trading (ELVN) With Integrated Risk Controls - news.stocktradersdaily.com

May 01, 2025

Apr 30, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Lowered by Legal & General Group Plc - Defense World

Apr 30, 2025

Apr 24, 2025

Enliven Therapeutics chief scientific officer sells $80,365 in stock By Investing.com - Investing.com India

Apr 24, 2025

Enliven Therapeutics chief scientific officer sells $80,365 in stock - Investing.com Australia

Apr 24, 2025

Apr 23, 2025